Friday, 19 Jul 2019

You are here

RheumNow Week in Review – The Heart Attack Report (11.2.18)

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

  1. Big news? Presented at #ACR18 as an abstract (L10) - small study of 29 primary Sjogrens syndrome pts - 8 Placebo vs 21 on Leflunomide + HCQ. At 24 weeks 1/9 PBO and 9/21 LEF/HCQ responded w/ ESSDAI improved > 3. Surprising, small, needs repeating https://t.co/xC4rA1JFIb
  2. CBC: neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) are significantly elevated in #RA and is as effective as CRP & ESR in correlating w/ DAS28-ESR https://t.co/K15vSHywfI https://t.co/xvqMWMqU0t
  3. Nationwide Inpatient Database (2005-2014) studied 2036 SLE patients with MI (STEMI and NonSTEMI) and showed hospital outcomes (Mortality, CABG, AE, hosp stay, costs) same as non-SLE patients. https://t.co/VpOrNh1fq0
  4. In contrast to RF, ACPA is not increased in HCV infection; among 271 HCV‐infected pts (no arthritis) they found 47% RF+, 1.1% ACPA+, 8.9% high‐positive RF, and 1.1% high‐positive ACPA. https://t.co/35wFgGVWcH
  5. Taiwan claims data shows that among 4036 psoriasis pts with HTN followed for 5.4 yrs, there was a 28% higher risk of cardiovascular procedures and surgery (aHR 1.28; 95% CI, 1.07-1.53); moreso in PsA and with severe psoriasis. https://t.co/cgpY8s3WDs
  6. Data from >50K commercial and Medicare claims in RA patients shows the risk of VTE (DVT/PE) to No different comparing pts on tofacitinib vs TNFi (HR 1.33; 95% CI, 0.78-2.24). Abst L09 #ACR18 https://t.co/dafoEcl9pD
  7. Amazing Single Center study using Methotrexate (~15/wk) prophylaxis in 10 pts starting IV pegloticase for refractory gout - ALL responded; no immunogenicity, no rise in SUA. Another way of preventing interference by anti-PEG Abs. #ACR18, Abstr #1286 https://t.co/D4oWLNYaPE
  8. Anti-phospholipid Antibodies and Myocardial Infarction   
  9. Spotlight on Interstitial Lung Disease at ACR 2018 
  10. RheumNow.Live  March 22-24, 2019 in Fort Worth Texas
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Don’t Take My Advice (7.19.19)

Dr. Jack Cush reports the news and new journal articles from the past week on RheumNow.com.

RheumNow Podcast – Boiling Hot MAS (7.12.19)

Dr. Jack Cush reviews this week's news and journal reports featured on RheumNow.com. PsA v. non-PsA pregnancies, Still's disease, lupus, nutritional supplements and dietary interventions, use of cannabis, tanezumab in OA, CBD oils and more.

Be ‘on point’: Guidelines for rheumatic complications of immunotherapy

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. At EULAR 2019, Madrid, several recommendations including RA, SLE, and Sjogren’s syndrome have been developed. Agreement for principles with respect to the treatment of immune mediated adverse events from cancer immunotherapy are lacking.

RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.

EULAR 2019 – Day 3 Report

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. The third day of EULAR 2019 started with novel biologics, the efficacy of secukinumab in axial psoriatic arthritis, neurologic events with TNF inhibitors from the DANBIO database (OP0261), and neuropathy in SLE (OP0252), but above all this was a big poster day. Here are selected highlights from day 3 EULAR in Madrid.